Two new mutations that collectively occur in 71 percent of malignant melanoma tumors have been discovered in what scientists call the "dark matter" of the cancer genome, where cancer-related mutations haven't been previously ...
Jan 24, 2013
0
0
New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer. Results of the BEACON CRC Phase III trial have shown that triple therapy targeting ...
Jul 6, 2019
0
0
Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease. Important advances in recent years include doctors ...
Apr 12, 2024
0
87
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination ...
Oct 20, 2013
0
0
(HealthDay)—For patients with metastatic melanoma treated with mitogen-activated protein kinase (MAPK) inhibitors, gender, serum lactate dehydrogenase (LDH), BRAF genotype, and primary melanoma ulceration status are independent ...
Aug 3, 2015
0
14
Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it.
Mar 6, 2012
0
0
Researchers at the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) have identified a new way of treating colorectal cancer. In the study published in the journal Science Signaling, the team led by LLuís Espinosa, ...
Apr 22, 2015
0
5
In the era of precision medicine, targeting the mutations driving cancer growth, rather than the tumor site itself, continues to be a successful approach for some patients. In the latest example, researchers from Penn Medicine ...
Jul 23, 2016
0
27
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase ...
Jul 6, 2019
0
2
A Massachusetts General Hospital (MGH) research team has identified an additional mechanism for resistance to targeted treatment for BRAF-mutant melanoma. Their paper, receiving advance online publication in Nature Medicine, ...
Aug 8, 2016
0
47
